Cytokinetics, Incorporated

About Cytokinetics, Incorporated

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Cytokinetics is a late-stage biopharmaceutical company focused on developing new medicines to patients with diseases like ALS, heart failure, and HCM.

https://www.cytokinetics.com

CYTK United States

50.39USD1.01 (+2.00%)

• At close Thu Oct 06 2022

NasdaqGS exchange

Sector: Healthcare

Industry: Biotechnology

Location United States, South San Francisco

Grade: ACF

3,634,342,912 USD
MARKET CAP
.
PE
0.799
BETA (5y)
-4.770
EPS

Profits

for 5 years
448%
for 3 years
310%
for 2 years
156%
for last year
52%
for this year
0%
Cytokinetics, Incorporated
© 2025 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.